| Location-routing problem A Hassanzadeh, L Mohseninezhad, A Tirdad, F Dadgostari, ... Facility location: concepts, models, algorithms and case studies, 395-417, 2009 | 33 | 2009 |
| Use of value of information in healthcare decision making: exploring multiple perspectives J Bindels, B Ramaekers, IC Ramos, L Mohseninejad, S Knies, J Grutters, ... Pharmacoeconomics 34, 315-322, 2016 | 31 | 2016 |
| Targeted screening for Coeliac Disease among irritable bowel syndrome patients: analysis of cost-effectiveness and value of information L Mohseninejad, T Feenstra, HE van der Horst, H Woutersen-Koch, ... The European Journal of Health Economics 14, 947-957, 2013 | 25 | 2013 |
| Evaluation of patient registries supporting reimbursement decisions: the case of oxaliplatin for treatment of stage III colon cancer L Mohseninejad, C van Gils, CA Uyl-de Groot, E Buskens, T Feenstra Value in health 18 (1), 84-90, 2015 | 15 | 2015 |
| Value of information analysis from a societal perspective: a case study in prevention of major depression L Mohseninejad, PHM van Baal, M van den Berg, E Buskens, T Feenstra Value in Health 16 (4), 490-497, 2013 | 14 | 2013 |
| Discretely Integrated Condition Event Simulation for Pharmacoeconomics M Toumi, E Beck, S Sherman, L Mohseninejad, S Aballéa PharmacoEconomics 34, 1187-1188, 2016 | 3 | 2016 |
| Uncertainty in economic evaluations: implications for healthcare decisions L Mohseninejad | 3 | 2013 |
| Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison M Shadman, A Tedeschi, L Mohseninejad, K Yang, N Lamanna, S Xu, ... Blood 142, 4655, 2023 | 1 | 2023 |
| A meta-analytic endpoint validation of surrogates used in clinical trials evaluating the efficacy of therapies in patients with chronic lymphocytic leukemia N Bahar, L Mohseninejad, K McDonald, T Wilke Hematological Oncology 41, 743-744, 2023 | 1 | 2023 |
| About the advantages and disadvantages of discrete-event simulation for health economic analyses M Toumi, E Beck, S Sherman, L Mohseninejad, S Aballéa Expert Review of Pharmacoeconomics & Outcomes Research 16 (6), 651-652, 2016 | 1 | 2016 |
| Matching-Adjusted Indirect Comparison (MAIC) of Zanubrutinib vs Ibrutinib in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) C Thieblemont, K Wang, S Keeping, I Zhang, K Yang, B Tang, ... | 1 | |
| SA23 Bruton Tyrosine Kinase Inhibitor (BTKi) Monotherapy for the Treatment of ‘High-Risk’Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL): A Systematic … L Mohseninejad, L Walder, S Ubi, A Malyon, K Yang, R Olie Value in Health 26 (12), S545, 2023 | | 2023 |
| EE667 Cost-Minimization Analysis (CMA) of Bruton Tyrosine Kinase Inhibitors (BTKi) in Adults with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) A Chanan-Khan, L Mohseninejad, L Walder, S Ubi, R Gani, A Shah, ... Value in Health 26 (12), S182, 2023 | | 2023 |
| EE516 Cost-Utility Analysis (CUA) in Chronic Lymphocytic Leukemia (CLL): Is COVID-19’s Impact on National Life Tables Important to Consider? L Mohseninejad, S Rivolo, A Rudas, B Peter, A Prieto, N Bahar, K Yang Value in Health 26 (12), S150-S151, 2023 | | 2023 |
| SA39 Targeted Treatments for Patients with Relapsed and/or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): A Systematic Literature Review (SLR) of Randomized Clinical … L Mohseninejad, L Walder, S Ubi, A Malyon, K Yang, R Olie Value in Health 26 (12), S548-S549, 2023 | | 2023 |
| SA57 Unmet Needs and Evidence Gaps in Relapsed/Refractory Marginal Zone Lymphoma: Findings from a Systematic Literature Review L Mohseninejad, S Deshpande, K Borkowska, P Wittkopf, K Yang, ... Value in Health 26 (12), S552, 2023 | | 2023 |
| CO130 Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend L Mohseninejad, T Srivastava, R Gautam, P Purkayastha, K Yang, V Lévy Value in Health 26 (12), S37, 2023 | | 2023 |
| Toxicity, Progression-Free Survival, and Quality of Life of Patients Treated with Zanubrutinib Versus Ibrutinib: A Q-TWiST Analysis from the ALPINE Study in Relapsed or … V Levy, T Srivastava, K Yang, P Purkayastha, R Gautam, K Wang, ... Blood 142, 1909, 2023 | | 2023 |
| Zanubrutinib vs FCR in Fit Treatment-Naive Patients with Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison T Munir, L Mohseninejad, S Xu, M Jevdjevic, W Bouwmeester, K Yang Blood 142, 6522, 2023 | | 2023 |
| PB1947: A META-ANALYTIC ENDPOINT VALIDATION OF SURROGATES USED IN CLINICAL TRIALS EVALUATING THE EFFICACY OF THERAPIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA N Bahar, L Mohseninejad, K Mcdonald, T Wilke HemaSphere 7 (S3), e641659a, 2023 | | 2023 |
